Get the Stockscreener App
1.58
6.04%
0.09
After Hours:
1.57
-0.01
-0.63%
Proqr Therapeutics N V stock is traded at $1.58, with a volume of 226.89K.
It is up +6.04% in the last 24 hours and up +2.60% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
See More
Previous Close:
$1.49
Open:
$1.52
24h Volume:
226.89K
Relative Volume:
0.55
Market Cap:
$166.47M
Revenue:
$17.91M
Net Income/Loss:
$-47.66M
P/E Ratio:
-3.4756
EPS:
-0.4546
Net Cash Flow:
$-62.63M
1W Performance:
-8.14%
1M Performance:
+2.60%
6M Performance:
-23.67%
1Y Performance:
-1.86%
1-Day Range:
$1.49
$1.58
1-Week Range:
$1.45
$1.69
52-Week Range:
$1.07
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.58 | 156.99M | 17.91M | -47.66M | -62.63M | -0.4546 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | Oppenheimer | Outperform |
| Apr-29-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts - Yahoo Finance UK
ProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline - TipRanks
ProQR (PRQR) schedules April 8 virtual event on Axiomer RNA pipeline - Stock Titan
Ahead of AX-0810 data, ProQR plans April 8 pipeline webcast - Stock Titan
If You Invested $1,000 in Proqr Therapeuti (PRQR) - Stock Titan
Evercore ISI Group Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Outperform Recommendation - MSN
Insider Sell: Can ProQR Therapeutics NV weather a recessionPortfolio Gains Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Research Analysts Set Expectations for PRQR Q2 Earnings - Defense World
ProQR (NASDAQ: PRQR) director details substantial share and long-dated option holdings - Stock Titan
ProQR (PRQR) CSO details sizeable option grants and share stake - Stock Titan
Director Maier details ProQR (PRQR) share option grants and vesting - Stock Titan
ProQR (PRQR) director Alison Lawton details multiple option grants - Stock Titan
ProQR (PRQR) CFO discloses 1,000,000-share option position in Form 3 - Stock Titan
Theresa Heggie (PRQR) details option and share holdings in Form 3 - Stock Titan
ProQR Therapeutics N.V. (PRQR) director files Form 3 for options - Stock Titan
ProQR (PRQR) CEO Daniel de Boer details long-dated option grants - Stock Titan
ProQR Therapeutics (PRQR) director reports five long-dated option grants - Stock Titan
ProQR Therapeutics (PRQR) director discloses share and option holdings - Stock Titan
Q2 Earnings Estimate for PRQR Issued By HC Wainwright - MarketBeat
Brokers Issue Forecasts for PRQR Q1 Earnings - MarketBeat
Aug Sentiment: Whats the RSI of ProQR Therapeutics NV stock2026 Highlights & Low Risk Profit Maximizing Plans - baoquankhu1.vn
ProQR Therapeutics N.V.Ordinary Shares (NQ: PRQR - The Chronicle-Journal
Recap Report: Is ProQR Therapeutics NV a strong candidate for buy and hold2026 Volume Leaders & AI Optimized Trade Strategies - baoquankhu1.vn
Breakout Zone: Is ProQR Therapeutics NV attractive for institutional investors2026 Opening Moves & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
ProQR Therapeutics NV earnings beat by €0.02, revenue topped estimates By Investing.com - Investing.com Australia
ProQR Therapeutics (NASDAQ:PRQR) Raised to Hold at Wall Street Zen - MarketBeat
ProQR Therapeutics NV earnings beat by €0.02, revenue topped estimates - Investing.com Nigeria
ProQR Therapeutics (NASDAQ:PRQR) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Citizens reiterates ProQR Therapeutics stock rating on RNA editing platform potential - Investing.com
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
PRQR SEC FilingsProqr Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) Coverage Initiated at Oppenheimer - MarketBeat
ProQR Therapeutics Q4 2025 Financial Results: Loss of $9.1MNews and Statistics - IndexBox
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
ProQR: Q4 Earnings Snapshot - marketscreener.com
ProQR Therapeutics NV reports results for the quarter ended December 31Earnings Summary - TradingView
ProQR Posts 2025 Results as Axiomer RNA Editing Pipeline Advances and Cash Runway Extends to Mid-2027 - TipRanks
ProQR (PRQR) Advances Clinical Trials Amid Reduced Cash Holdings - GuruFocus
ProQR Therapeutics (NASDAQ: PRQR) details 2025 loss, cash runway and RNA editing focus - Stock Titan
ProQR Announces Year End 2025 Operating and Financial Results - weeklyvoice.com
ProQR (Nasdaq: PRQR) widens 2025 loss as R&D spending rises - Stock Titan
ProQR: Fourth Quarter Financial Overview - Bitget
Analysts Set ProQR Therapeutics Price Target at $7.14 - National Today
ProQR Therapeutics NV expected to post a loss of 10 cents a shareEarnings Preview - TradingView
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Quarterly Risk: Can ProQR Therapeutics NV weather a recession2025 Big Picture & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Weekly Trades: Is ProQR Therapeutics NV backed by strong institutional buyingJuly 2025 Pullbacks & Verified Momentum Stock Alerts - baoquankhu1.vn
Highs Report: Is ProQR Therapeutics NV a strong candidate for buy and holdMarket Growth Review & Real-Time Buy Signal Notifications - baoquankhu1.vn
Portfolio Shifts: Can ProQR Therapeutics NV benefit from deglobalization2025 Market Sentiment & AI Forecasted Stock Moves - baoquankhu1.vn
Is ProQR Therapeutics NV backed by strong institutional buyingWeekly Trend Recap & Risk Controlled Daily Plans - baoquankhu1.vn
Retinitis Pigmentosa Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc - Barchart.com
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):